Search

Search Constraints

You searched for: Author/Creator Loft, Anne Gitte

Search Results

11. Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis. (18th August 2018)

12. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. Issue 3 (19th September 2020)

13. Effectiveness of interdisciplinary combined dermatology–gastroenterology–rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. Issue 4 (28th April 2021)

14. Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. Issue 6 (4th June 2019)

15. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. (23rd December 2021)

16. FRI0378 DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? – RESULTS FROM THE EUROSPA RESEARCH COLLABORATION. (June 2019)

17. FRI0403 HIGH BASELINE PATIENT'S COMPARED WITH EVALUATOR'S GLOBAL ASSESSMENT IS ASSOCIATED WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS – DATA FROM THE EUROSPA COLLABORATION. (June 2019)

18. FRI0404 POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION. (June 2019)

19. FRI0453 DOES DISCORDANCE BETWEEN BASELINE PATIENT'S AND EVALUATOR'S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IMPACT RETENTION AND REMISSION RATES OF TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS? DATA FROM THE EUROSPA RESEARCH COLLABORATION. (June 2019)

20. Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries. Issue 6 (28th February 2020)